Cancer Research and Treatment

Case Report

Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission: Won Sup Lee, Ji-Hyen Hwang, Moon Jin Kim, Se-Il Go, Anna Lee, Haa-Na Song, Min Jeong Lee, Myung Hee Kang, Hoon-Gu Kim, Jeong-Hee Lee; Cancer Res Treat. 2014;46(3):312-316. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.312

Subcutaneous panniculitis-like T cell lymphoma (SPTL) is a distinctive cutaneous lymphoma characterized by an infiltration of subcutaneous tissue by neoplastic T cells, similar to panniculitis. It is well-established that patients who are diagnosed with SPTL usually respond poorly to chemotherapy, showing fatal outcome. As a first line treatment for SPTL, anthracycline-based chemotherapy was most frequently used. For the treatment of SPTL, the efficacy of cyclosporine A has been recently reported in relapsed SPTL after anthracycline-based chemotherapy. However, it is still not clear whether cyclosporine A can be used as a first-line treatment against SPTL. Here, we report a case of SPTL, which achieved complete remission for nine years after first-line cyclosporine A therapy. This study suggests that cyclosporine A can induce a complete long-term remission as a first-line treatment.

Citations

Citations to this article as recorded by

The pathophysiology and current treatments for the subcutaneous panniculitis‐like T cell lymphoma: An updated review
En‐Cheng Lin, Jia‐Bin Liao, Yu‐Han Fang, Chien‐Hui Hong
Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 27. CrossRef
A retrospective study of 18 children with subcutaneous panniculitis-like T-cell lymphoma: multidrug combination chemotherapy or immunomodulatory therapy?
Yanlong Duan, Huixia Gao, Chunju Zhou, Ling Jin, Jing Yang, Shuang Huang, Meng Zhang, Yonghong Zhang, Tianyou Wang
Orphanet Journal of Rare Diseases.2022;[Epub] CrossRef
Case Report—Indurated Plaques and Recurrent Fevers in a 37-Year-Old Man: Answer
Elizabeth Dao, Alexandra Bourgeois, Pamela Martin
The American Journal of Dermatopathology.2021; 43(10): 754. CrossRef
Hemophagocytic Lymphohistiocytosis as the Initial Presentation of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Rare Case Responding to Cyclosporine A and Steroids
Caitlin Sullivan, Arya Loghmani, Katharine Thomas, Rachna Jetly-Shridhar, Rajasree Pia Chowdry
Journal of Investigative Medicine High Impact Case Reports.2020;[Epub] CrossRef
Rare Cutaneous T-Cell Lymphomas
Fabiana Damasco, Oleg E. Akilov
Hematology/Oncology Clinics of North America.2019; 33(1): 135. CrossRef
Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population
Ting-An Lin, Ching-Fen Yang, Yao-Chung Liu, Jin-Hwang Liu, Tzeon-jye Chiou, Liang-Tsai Hsiao, Hsiu-Ju Yen, Chia-Jen Liu, Hao-Yuan Wang, Po-Shen Ko, Sheng-Hsuan Chien, Jyh-Pyng Gau
International Journal of Hematology.2019; 109(2): 187. CrossRef
Successful treatment of a rare subcutaneous panniculitis‐like T‐cell lymphoma: An unusual case report and literature review
Liye Xu, Yuxuan Che, Xiaolei Ding, Jincheng Song, Xian Zhang, Xiuhua Sun
Dermatologic Therapy.2019;[Epub] CrossRef
British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018
J. Berth‐Jones, L.S. Exton, E. Ladoyanni, M.F. Mohd Mustapa, V.M. Tebbs, P.D. Yesudian, N.J. Levell, P.M. McHenry, T.A. Leslie, S. Wakelin, R.Y.P. Hunasehally, M. Cork, G.A. Johnston, N. Chiang, F.S. Worsnop, A. Salim, D. Buckley, G. Petrof, N. Callachand
British Journal of Dermatology.2019; 180(6): 1312. CrossRef
A Systematic Approach to the Cutaneous Lymphoid Infiltrates: A Clinical, Morphologic, and Immunophenotypic Evaluation
Alejandro A. Gru, Chauncey McHargue, Andrea L. Salavaggione
Archives of Pathology & Laboratory Medicine.2019; 143(8): 958. CrossRef
Hemophagocytic lymphohistiocytosis: A rare, potentially fatal complication in subcutaneous panniculitis like T cell lymphoma
ChandraSekhar Sirka, Swetalina Pradhan, Susama Patra, Somanath Padhi, SarojKumar DasMajumdar, Debjani Panda
Indian Journal of Dermatology, Venereology and Leprology.2019; 85(5): 481. CrossRef
Subcutaneous panniculitis-like T-Cell lymphoma: A mixed diagnostic approach to diagnosing a vague clinical picture
Callie Roberts Hill, Apphia Wang, Boni E. Elewski, Peter G Pavlidakey
SKIN The Journal of Cutaneous Medicine.2019; 3(2): 90. CrossRef
Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas
Pilvi Maliniemi, Kirsi Laukkanen, Liisa Väkevä, Katja Dettmer, Tuomas Lipsanen, Leila Jeskanen, Alban Bessede, Peter J. Oefner, Marshall E. Kadin, Annamari Ranki
OncoImmunology.2017; 6(3): e1273310. CrossRef
Uncommon Variants of T-Cell Lymphomas
Neha Mehta-Shah, Steven Horwitz
Hematology/Oncology Clinics of North America.2017; 31(2): 285. CrossRef
Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review
Chi-Ching Chen, Chieh-Lin Teng, Su-Peng Yeh
Annals of Hematology.2016; 95(5): 837. CrossRef
Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides
Meenal Kheterpal, Neha Mehta-Shah, Pooja Virmani, Patricia L. Myskowski, Alison Moskowitz, Steven M. Horwitz
Current Hematologic Malignancy Reports.2016; 11(3): 224. CrossRef
Zebras and hen's teeth: recognition and management of rare T and NK lymphomas
Neha Mehta–Shah, Steven Horwitz
Hematology.2015; 2015(1): 545. CrossRef

11,686 View
91 Download
16 Web of Science
16 Crossref

Original Article

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies: Min Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kang; Cancer Res Treat. 2012;44(4):235-241. Published online December 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.4.235

Abstract PDF PubReader ePub

PURPOSE
Little is known about outcomes in the use of third-line chemotherapy in cases of advanced gastric cancer (AGC). The primary aim of this retrospective study was to evaluate outcomes of docetaxel-based chemotherapy in patients with AGC that progressed after both oxaliplatin-based and irinotecan-based regimens.
MATERIALS AND METHODS
Eligible patients were those with AGC who had previous chemotherapy including fluoropyrimidine and oxaliplatin as well as fluoropyrimidine and irinotecan and who received subsequent docetaxel-based chemotherapy. Thirty-five patients were retrospectively recruited from 5 medical centers in Korea. Patients received either weekly or 3 weekly with docetaxel +/- cisplatin.
RESULTS
Thirty-one out of 35 patients were evaluated for treatment response. A total of 94 cycles of chemotherapy (median, 2; range, 1 to 7) were administered. The overall response rate was 14.3%, and the disease control rate was 45.7%. The median progression-free survival (PFS) was 1.9 months (95% confidence interval [CI], 1.1 to 2.7 months). The median overall survival (OS) was 3.6 months (95% CI, 2.8 to 4.4 months). PFS and OS were significantly prolonged in patients of the Eastern Cooperative Oncology Group, with performance status of 0 or 1 in multivariate analysis (PFS: hazard ratio[HR], 0.411; 95% CI, 0.195 to 0.868; p=0.020 and OS: HR, 0.390; 95% CI, 0.184 to 0.826; p=0.014, respectively). Four of the 35 patients enrolled in the study died due to infection associated with neutropenia.
CONCLUSION
Our findings suggest that salvage docetaxel-based chemotherapy is a feasible treatment option for AGC patients with good performance status (PS), whereas chemotherapy for patients with poor PS (PS< or =2) should be undertaken with caution for those who previously failed oxaliplatin- and irinotecan-based regimens.

Citations

Citations to this article as recorded by

Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
In-Ho Kim, Seung Joo Kang, Wonyoung Choi, An Na Seo, Bang Wool Eom, Beodeul Kang, Bum Jun Kim, Byung-Hoon Min, Chung Hyun Tae, Chang In Choi, Choong-kun Lee, Ho Jung An, Hwa Kyung Byun, Hyeon-Su Im, Hyung-Don Kim, Jang Ho Cho, Kyoungjune Pak, Jae-Joon Kim
Journal of Gastric Cancer.2025; 25(1): 5. CrossRef
Assessment of novel prognostic biomarkers to predict pathological complete response in patients with non-metastatic triple-negative breast cancer using a window of opportunity design
Chitradurga Rajashekhar Akshatha, Dhanapathi Halanaik, Rajesh Nachiappa Ganesh, Nanda Kishore, Prasanth Ganesan, Smita Kayal, Harichandra Kumar, Biswajit Dubashi
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
HTA and Gastric Cancer: Evaluating Alternatives in Third- and Fourth-Line Patients
Lucrezia Ferrario, Federica Asperti, Giuseppe Aprile, Jacopo Giuliani
International Journal of Environmental Research and Public Health.2023; 20(3): 2107. CrossRef
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
Journal of Gastric Cancer.2023; 23(1): 3. CrossRef
A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines
Sang Soo Eom, Wonyoung Choi, Bang Wool Eom, Sin Hye Park, Soo Jin Kim, Young Il Kim, Hong Man Yoon, Jong Yeul Lee, Chan Gyoo Kim, Hark Kyun Kim, Myeong-Cherl Kook, Il Ju Choi, Young-Woo Kim, Young Iee Park, Keun Won Ryu
Journal of Gastric Cancer.2022; 22(1): 3. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
What is the value of third‐line chemotherapy in advanced gastroesophageal cancer? A 5‐year retrospective analysis at a single center
Justina Yick Ching Lam, Su Pin Choo, David Wai‐Meng Tai, Iain Bee Huat Tan, Chee Kian Tham, Wen Hsin Koo, Simon Yew Kuang Ong, Soo Fan Ang, Clarinda Wei Ling Chua, Dawn Qingqing Chong, Patrick Tze Hern Teo, Christabel Jing Zhi Lee, Samuel Cheng En Ee, Mat
Asia-Pacific Journal of Clinical Oncology.2020; 16(1): 23. CrossRef
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach

Journal of Gastric Cancer.2019; 19(1): 1. CrossRef
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
Giandomenico Roviello, Alberto D’Angelo, Raheleh Roudi, Roberto Petrioli, Enrico Mini
Journal of Oncology.2019; 2019: 1. CrossRef
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
In Sil Choi, Mihong Choi, Ju Hyun Lee, Jee Hyun Kim, Koung Jin Suh, Ji Yun Lee, Beodeul Kang, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
PLOS ONE.2018; 13(6): e0198544. CrossRef
The role of third-line chemotherapy in recurrent or metastatic gastric cancer
Yong Won Choi, Mi Sun Ahn, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Seung Soo Sheen
Medicine.2018; 97(39): e12588. CrossRef
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends
P. Edwards, M. Davidson, V. Calamai, D. Cunningham, N. Starling
Cancer Treatment Reviews.2018; 71: 32. CrossRef
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
Takashi Nishimura, Satoru Iwasa, Kengo Nagashima, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Narikazu Boku
Gastric Cancer.2017; 20(4): 655. CrossRef
Advanced gastric cancer: is there an optimal chemotherapy regimen?
Kalliopi Andrikou, Massimiliano Salati, Annalisa Fontana, Andrea Spallanzani, Stefania Pipitone, Fabio Gelsomino, Monica Barbolini, Stefano Cascinu
Expert Review of Quality of Life in Cancer Care.2017; 2(2): 123. CrossRef
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis
Wing-lok Chan, Kwok-keung Yuen, Steven Wai-kwan Siu, Ka-on Lam, Dora Lai-wan Kwong
Critical Reviews in Oncology/Hematology.2017; 116: 68. CrossRef
Third-line chemotherapy in advanced gastric cancer
Yu Zheng, Xu-Qing Zhu, Xiao-Gang Ren
Medicine.2017; 96(24): e6884. CrossRef
Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?
Massimiliano Salati, Katia Di Emidio, Vittoria Tarantino, Stefano Cascinu
ESMO Open.2017; 2(3): e000206. CrossRef
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone,
The Oncologist.2017; 22(12): 1463. CrossRef
Metastatic gastric cancer treatment: Second line and beyond
Marwan Ghosn, Samer Tabchi, Hampig Raphael Kourie, Mustapha Tehfe
World Journal of Gastroenterology.2016; 22(11): 3069. CrossRef
A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)
Yoon-Koo Kang, Baek-Yeol Ryoo, Shinkyo Yoon, Lin Shen, Jooyun Lee, Chenlu Wei, Yu Zhou, Min-Hee Ryu
Cancer Chemotherapy and Pharmacology.2015; 75(2): 309. CrossRef
Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer
BYUNG HA CHO, HYE SOOK HAN, JIHYUN KWON, JOUNG-HO HAN, SOON MAN YOON, DAE HOON KIM, HYO YUNG YUN, KI HYEONG LEE, SEI JIN YOUN, SEUNG TAIK KIM
Oncology Letters.2015; 10(4): 2481. CrossRef
Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
Hugo Ford, Ioannis Gounaris
Therapeutic Advances in Gastroenterology.2015; 8(4): 189. CrossRef
Chemotherapy beyond second-line in advanced gastric cancer
Sung Min Kim
World Journal of Gastroenterology.2015; 21(29): 8811. CrossRef
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study
Yulong Zheng, Weijia Fang, Chenyu Mao, Joing Qian, Peng Zhao, Xiaochen Zhang, Haiping Jiang, Yi Zheng, Nong Xu
Cancer Chemotherapy and Pharmacology.2014; 74(3): 503. CrossRef

62,822 View
95 Download
24 Crossref

First
Prev
Page of 1
Next
Last

Search